Institut National De La Sante Et De La Recherche Medicale

Institut Gustave Roussy

Applied Research Systems Ars Holding N.v.

Immutep S.a.s.

Roussel Uclaf

Aventis Pharma S.a.

Immutep

Other

Hoechst Marion Roussel

Immutep Parc Club Orsay

Immutep S.a.

Novartis Ag

Frederic Triebel

Thierry Hercend

Sergio Roman-Roman

Laurent Ferradini

Chrystelle Brignone

Bertrand Huard

Florence Faure

Gerhard Johann Frey

Hwai Wen Chang

Walter A Blattler

Karin Ute Jooss

Bernard Vanhove

Jennifer Marie Mataraza

Catherine Anne Sabatos-Peyton

Betty Li

Nabil El Tayar

Renato Mastrangeli

Thomas Haudebourg

Combined preparations for the treatment of cancer are described. The combined preparations comprise: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) an anti-neoplastic agent, wherein the anti-neoplastic agent is a platinum-based anti-neoplastic agent or a topoisomerase I inhibitor. Methods for the treatment of cancer using the combined preparations are also described.

Combined preparations for the treatment of cancer

Combined preparations, and pharmaceutical compositions, comprising: (a) LAG-3 protein, or a derivative thereof that is able to bind to MHC class II molecules; and (b) a programmed cell death protein-1 (PD-1) pathway inhibitor, are described. The PD-1 pathway inhibitor, such as an anti-PD-1 antibody or an anti-PD-L1 antibody, and a soluble derivative of LAG-3, acting as an APC activator, together synergistically activate T cells (in particular, CD8T cells). Use of the combined preparations and compositions as medicaments, in particular for the treatment of cancer or infection, and to methods for the treatment of cancer or infection, is described.

Combined preparations for the treatment of cancer or infection

The present invention relates to the use of a recombinant LAG-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.

Use of recombinant LAG-3 or the derivatives thereof for eliciting monocyte immune response

Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.

Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease

The present invention relates to new nucleotide sequences coding for variable regions of &#x3b2; chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses.

Nucleotide sequence coding for variable regions of &#x3b2; chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

The present invention relates to a method of enhancing anti-tumor protection in a mammal. More particularly, the invention is concerned with combinations comprising antigen presenting cell (APC) activators and a cytokine-secreting cell and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.

Compositions containing LAG-3 and cells that secrete GM-CSF and methods of use

Nucleotide sequences coding for variable regions of &#x3b2; chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer-immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen able to induce an antigen-specific immune response together with an effective amount of a MHC class II ligand wherein said MHC class II ligand is present as an adjuvant-like agent.

Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment

Nucleotide sequences coding for variable regions of the alpha chains of human T lymphocyte receptors, corresponding peptide segments and the diagnostic and therapeutic uses

The invention concerns a purified polypeptide corresponding to a mutated form of the soluble LAG-3 protein or of one of its fragments comprising the extra-cellular domain D1 and D2.

Mutants of the LAG-3 proteins and nucleotides encoding LAG-3 mutants

The present invention concerns the use of a MHC class II ligand, LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen together with an effective amount of human LAG-3, wherein LAG-3 s present as an adjuvant.

Growing community of inventors

Versailles, France

Frederic Triebel